The Cost-disruptive novel screening and diagnosis tools program under GCI seeks transformative novel tools or approaches or devices and ultra-low-cost solutions for screening and/or diagnostics prioritizing near point-of-care and low-incremental-cost formats that can meet real-world operational constraints and really disrupt the accessibility and availability landscape.


